CheckMate 141 trial: all that glitters is not gold-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

CheckMate 141 trial: all that glitters is not gold

Published:2019-01-21 Issue:3 Volume:19 Page:169-171
ISSN:1471-2598
Container-title:Expert Opinion on Biological Therapy
language:en
Short-container-title:Expert Opinion on Biological Therapy

Author:

Addeo Raffaele¹,Ghiani Massimo²,Merlino Francesco³,Ricciardiello Filippo⁴,Caraglia Michele⁵^ORCID

Affiliation:

1. Oncology Unit, “S. Giovanni di Dio” Hospital, Naples, Italy

2. Oncology Unit, “Businco” Hospital, Cagliari, Italy

3. Department of Pharmacy, University of Naples Federico II, Naples, Italy

4. U.O.C. ORL, AORN “Cardarelli”, Napoli, Italy

5. Department of Precision Medicine, University of Campania “L. Vanvitelli”, Naples and Biogem, Avellino Italy

Publisher

Informa UK Limited

Subject

Clinical Biochemistry,Drug Discovery,Pharmacology

Link

https://www.tandfonline.com/doi/pdf/10.1080/14712598.2019.1570498

Reference11 articles.

1. Nivolumab for Recurrent Squamous-Cell Carcinoma of the Head and Neck

2. Evidence-Based Treatment Options in Recurrent and/or Metastatic Squamous Cell Carcinoma of the Head and Neck

3. Afatinib versus methotrexate as second-line treatment in patients with recurrent or metastatic squamous-cell carcinoma of the head and neck progressing on or after platinum-based therapy (LUX-Head & Neck 1): an open-label, randomised phase 3 trial

4. Pembrolizumab: the value of PDL1 biomarker in head and neck cancer

Cited by 13 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Is the use of cetuximab in the first-line treatment of recurrent/metastatic head and neck cancer still important?;Expert Review of Anticancer Therapy;2024-05-13

2. Spatial mapping reveals unique cellular interactions and enhanced tertiary lymphoid structures in responders to anti-PD-1 therapy in mucosal head and neck cancers;2024-04-21

3. ELOVL6 promotes the progression of head and neck squamous cell carcinoma via activating WNT/β‐catenin pathway;Molecular Carcinogenesis;2024-03

4. Personalised Medicine and the Potential Role of Electrospinning for Targeted Immunotherapeutics in Head and Neck Cancer;Nanomaterials;2023-12-19

5. Unlocking antitumor immunity with adenosine receptor blockers;Cancer Drug Resistance;2023-10-23

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3